SEARCH

SEARCH BY CITATION

Fig. S1. Pathway analysis of the differentially expressed genes in allergen-challenged PBMCs. Differentially expressed genes in patients vs. healthy controls were submitted to Ingenuity Pathway Analysis (IPA). Pathways above the threshold have a P<0.05. Yellow square represents the ratio of differentially expressed genes in each pathway.

Fig. S2. The percentage of basophils in CD4-CRTH2high cells from PBMCs. Freshly isolated PBMCs from buffy coat were stained with mouse anti-CD4-FITC, rat anti-CRTH2-PE, mouse anti-HLA-DR-PerCP and mouse anti-CD123-APC. The percentage of CD4-CRTH2high cells in gated CD123+HLA-DR- cells (down) and CD123+HLA-DR- cells in gated CD4-CRTH2high cells (upper) were counted by Cellquest analysis.

Fig. S3. Activation of IL-17RB does not affect the expression of adhesion molecules on basophils. PBMCs from buffy coat were treated with or without IL-25 for one hour (a) and 18 h (b), respectively. Representative histograms are from one of four individuals. Shaded histogram represents isotype control; broken line represents no treatment; solid line represents treatment with IL-25.

Table S1. The fold change of differentially expressed genes in allergen-challenged PBMCs from Patients with SAR vs. healthy controls

Please note: Wiley-Blackwell is not responsible for the content or functionality of any supporting materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.

FilenameFormatSizeDescription
CEA_3542_sm_f1-3.pdf186KSupporting info item
CEA_3542_sm_t1.pdf22KSupporting info item

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.